Protagenic Therapeutics, Inc.\new Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net
Protagenic Therapeutics, Inc.\new (PTIX) had Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net of $2.34 million as of 2025-05-15, per its 10-Q filed 2026-08-19.
Financial Statements › Notes › Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation › Business Combination, Recognized Asset Acquired to Liability Assumed, Excess (Less), and Goodwill
us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet · last filed 2026-08-19
- 2025-05-15: Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net $2.34M.
| Period end | Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net |
|---|---|
| 2025-05-15 | $2.34M 10-Q · filed 2026-08-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| Rafael Holdings, Inc. (RFL) | United States | $0.000B | -0.00 |